Y. Yalçınkaya Et Al. , "ANTI-FIBROTIC THERAPY IN PROGRESSIVE PULMONARY FIBROSIS ASSOCIATED WITH SYTEMIC SCLEROSIS: CHARACTERISTICS OF SSC-ILD PATIENTS RECEIVING NINTEDANIB AND ADVERS EVENTS DURING TREATMENT," 7 th Systemic Sclerosis Congress , pp.1, 2022
Yalçınkaya, Y. Et Al. 2022. ANTI-FIBROTIC THERAPY IN PROGRESSIVE PULMONARY FIBROSIS ASSOCIATED WITH SYTEMIC SCLEROSIS: CHARACTERISTICS OF SSC-ILD PATIENTS RECEIVING NINTEDANIB AND ADVERS EVENTS DURING TREATMENT. 7 th Systemic Sclerosis Congress , 1.
Yalçınkaya, Y., Amikishiyev, S., Aliyeva, N., Artım Esen, B., Bingöl, Z., Okumuş, N. G., ... İnanç, M.(2022). ANTI-FIBROTIC THERAPY IN PROGRESSIVE PULMONARY FIBROSIS ASSOCIATED WITH SYTEMIC SCLEROSIS: CHARACTERISTICS OF SSC-ILD PATIENTS RECEIVING NINTEDANIB AND ADVERS EVENTS DURING TREATMENT . 7 th Systemic Sclerosis Congress (pp.1).
Yalçınkaya, Yasemin Et Al. "ANTI-FIBROTIC THERAPY IN PROGRESSIVE PULMONARY FIBROSIS ASSOCIATED WITH SYTEMIC SCLEROSIS: CHARACTERISTICS OF SSC-ILD PATIENTS RECEIVING NINTEDANIB AND ADVERS EVENTS DURING TREATMENT," 7 th Systemic Sclerosis Congress, 2022
Yalçınkaya, Yasemin Et Al. "ANTI-FIBROTIC THERAPY IN PROGRESSIVE PULMONARY FIBROSIS ASSOCIATED WITH SYTEMIC SCLEROSIS: CHARACTERISTICS OF SSC-ILD PATIENTS RECEIVING NINTEDANIB AND ADVERS EVENTS DURING TREATMENT." 7 th Systemic Sclerosis Congress , pp.1, 2022
Yalçınkaya, Y. Et Al. (2022) . "ANTI-FIBROTIC THERAPY IN PROGRESSIVE PULMONARY FIBROSIS ASSOCIATED WITH SYTEMIC SCLEROSIS: CHARACTERISTICS OF SSC-ILD PATIENTS RECEIVING NINTEDANIB AND ADVERS EVENTS DURING TREATMENT." 7 th Systemic Sclerosis Congress , p.1.
@conferencepaper{conferencepaper, author={Yasemin YALÇINKAYA Et Al. }, title={ANTI-FIBROTIC THERAPY IN PROGRESSIVE PULMONARY FIBROSIS ASSOCIATED WITH SYTEMIC SCLEROSIS: CHARACTERISTICS OF SSC-ILD PATIENTS RECEIVING NINTEDANIB AND ADVERS EVENTS DURING TREATMENT}, congress name={7 th Systemic Sclerosis Congress}, city={}, country={}, year={2022}, pages={1} }